Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Olema Oncology (Nasdaq: OLMA) announced a proposed public offering of common stock and, for some investors, pre-funded warrants, subject to market and other conditions.
The offering is to be made from a shelf registration on Form S-3 declared effective January 15, 2025. Olema expects to grant underwriters a 30-day option to buy up to an additional 15% of the total shares and shares underlying the pre-funded warrants. TD Cowen is acting as book-running manager. No assurance exists regarding timing, size, or terms; a preliminary prospectus supplement will be filed with the SEC and made available on SEC.gov.
Olema Oncology (Nasdaq: OLMA) ha annunciato una proposta di offerta pubblica di azioni ordinarie e, per alcuni investitori, di warrant prefinanziati, soggetta a condizioni di mercato e ad altre condizioni.
L'offerta sarà effettuata mediante una shelf registration su Form S-3 dichiarato efficace il 15 gennaio 2025. Olema prevede di concedere agli underwriters una opzione di 30 giorni per acquistare fino a un ulteriore 15% delle azioni totali e delle azioni sottostanti i warrant prefinanziati. TD Cowen agisce come book-running manager. Non esistono garanzie riguardo tempistica, dimensione o termini; un supplemento preliminare al prospetto sarà depositato presso la SEC e reso disponibile su SEC.gov.
Olema Oncology (Nasdaq: OLMA) anunció una oferta pública propuesta de acciones comunes y, para algunos inversores, warrants prefinanciados, sujeto a condiciones de mercado y otras condiciones.
La oferta se realizará mediante un registro en estantería (shelf registration) en el Formulario S-3 declarado eficaz el 15 de enero de 2025. Olema espera otorgar a los underwriters una opción de 30 días para comprar hasta un adicional 15% de las acciones totales y de las acciones subyacentes a los warrants prefinanciados. TD Cowen actúa como book-running manager. No hay certeza respecto a fecha, tamaño o términos; se presentará un suplemento preliminar de prospecto ante la SEC y estará disponible en SEC.gov.
Olema Oncology (나스닥: OLMA)가 일반주 및 일부 투자자에 대해서는 선충전(pre-funded) 워런트의 공개공모를 제안했다고 발표했습니다. 이는 시장 조건 등 여러 조건에 따라 좌우됩니다.
공모는 2025년 1월 15일에 효력이 발생한 Form S-3의 shelf 등록을 통해 이루어질 예정입니다. Olema는 주관사에게 총 주식 수의 추가 분으로 최대 15%와 선충전 워런트의 기초 주식을 매수할 수 있는 30일 간의 옵션을 부여할 것으로 기대합니다. TD Cowen은 북런 관리 책임자로서 역할합니다. 시기, 규모, 조건에 대한 보장은 없으며, 예비 투자설명서가 SEC에 제출되고 SEC.gov에서 제공될 예정입니다.
Olema Oncology (Nasdaq: OLMA) a annoncé une offre publique proposée d'actions ordinaires et, pour certains investisseurs, de warrants préfinancés, sous réserve des conditions du marché et d'autres conditions.
L'offre doit être réalisée à partir d'un enregistrement de type shelf sur le formulaire S-3 déclaré efficace le 15 janvier 2025. Olema prévoit d'accorder aux assureurs une option de 30 jours pour acheter jusqu'à un additionnel 15% du total des actions et des actions sous-jacentes aux warrants préfinancés. TD Cowen agit en tant que book-running manager. Il n'existe aucune garantie concernant le calendrier, la taille ou les termes; un supplément de prospectus préliminaire sera déposé auprès de la SEC et mis à disposition sur SEC.gov.
Olema Oncology (Nasdaq: OLMA) kündigte eine vorgeschlagene öffentliche Platzierung von Stammaktien an und für einige Investoren auch pre-financed Warrants, abhängig von Marktbedingungen und anderen Bedingungen.
Das Angebot soll über eine Shelf-Registration auf Formular S-3 erfolgen, das am 19. Januar 2025 wirksam geworden ist. Olema beabsichtigt, den Underwritern eine 30-tägige Option zu gewähren, bis zu zusätzlich 15% der Gesamtaktien und der Aktien unter den pre-financed Warrants zu kaufen. TD Cowen fungiert als Book-Running Manager. Es gibt keine Zusagen bezüglich Timing, Größe oder Bedingungen; ein vorläufiger Prospekt-Supplement wird bei der SEC eingereicht und unter SEC.gov verfügbar gemacht.
Olema Oncology (ناسداك: OLMA) أعلنت عن عرض عام مقترح لــالأسهم العادية وبالنسبة لبعض المستثمرين الأوراق المسبقة التمويل (pre-funded warrants)، خاضع لشروط السوق وشروط أخرى.
سيتم العرض من خلال تسجيل رفّ (shelf registration) على النموذج S-3 الذي أصبح ساري المفعول في 15 يناير 2025. تتوقع Olema منح المكتتبين خياراً لمدة 30 يوماً لشراء ما يصل إلى 15% إضافية من إجمالي الأسهم والأسهم الأساسية المرتبطة بالأوراق المسبقة التمويل. يعمل TD Cowen كمدير مكتبة (book-running manager). لا توجد تأكيدات بخصوص التوقيت أو الحجم أو الشروط؛ سيُقدَّم ملحق تمهيدي للنشرة إلى هيئة الأوراق المالية والسلع وسيكون متاحاً على SEC.gov.
- Shelf registration effective Jan 15, 2025
- TD Cowen appointed book-running manager
- Offering includes pre-funded warrants option for some investors
- Underwriters may purchase +15% via 30-day option
- Proposed public offering may dilute existing shareholders
- No assurance on timing, size, or terms of the offering
Insights
Olema plans an at-the-market public offering of equity/pre-funded warrants; this is a standard capital raise with potential dilution.
Olema proposes to sell shares of common stock or pre-funded warrants to raise capital, with TD Cowen as book-running manager and a 30-day underwriter option to purchase up to
The primary business mechanism is straightforward: issue equity (or pre-funded warrants for certain investors) to obtain cash for operations or programs. Key dependencies include market conditions, final offering size and pricing, and investor demand; each will determine dilution and net proceeds. The underwriter option increases potential dilution by up to
Watch for the preliminary prospectus supplement filing and the terms it contains, including aggregate shares offered, offering price, and net proceeds; timing and execution risk center on market receptivity and timing between this announcement (
SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell shares of its common stock, or for certain investors that so choose, in lieu of shares of common stock, pre-funded warrants to purchase shares of its common stock. All of the securities are being offered by Olema.
In connection with the proposed offering, Olema expects to grant the underwriters a 30-day option to purchase up to an additional
TD Cowen is acting as book-running manager for the proposed offering.
The proposed offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed with the Securities and Exchange Commission (the “SEC”) on January 6, 2025 and declared effective on January 15, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering may be obtained, when available from: TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Olema’s lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective ER degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “anticipate,” “expect,” “may,” “plan,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include, among others, statements regarding the timing, terms, size and completion of the proposed public offering and the anticipated grant to the underwriters of an option to purchase additional shares. Because such statements deal with future events and are based on Olema’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, those discussed in the section titled “Risk Factors” in Olema’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, the preliminary prospectus supplement related to the proposed public offering and other filings and reports that Olema makes from time to time with the SEC. Except as required by law, Olema assumes no obligation to update these forward-looking statements, including in the event that actual results differ materially from those anticipated in the forward-looking statements.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What is Olema Oncology (OLMA) offering in the November 18, 2025 announcement?
Who is the book-running manager for Olema Oncology's proposed offering (OLMA)?
When was Olema's shelf registration declared effective for the OLMA offering?
Will underwriters have an option in the OLMA offering and how large is it?
Where can investors find Olema Oncology's preliminary prospectus supplement for the OLMA offering?
